Recent advances in asthma mucus biology and emerging treatment strategies

Purpose of review To describe the recent advances in the pathobiology and treatment of mucus hypersecretion in asthma, a critical factor contributing to airway obstruction, inflammation, and impaired lung function. Recent findings Significant progress has been made in understanding how mucin protein regulation, mucus viscosity, and adhesion are affected by cytokine-driven inflammation, especially interleukin-13, and defects in ion transport mechanisms. Advances in imaging techniques, such as multidetector computed tomography (MDCT) and hyperpolarized gas MRI, allow for a more precise assessment of mucus plugging and associated ventilation defects. Emerging therapies, including biologicals targeting type-2 (T2) inflammation, and novel mucolytics aimed at modifying mucus properties and secretion, offer promising effects in reducing mucus in severe asthmatics. Summary The growing understanding of mucus biology and the development of advanced imaging and therapeutic strategies could significantly improve the management of mucus-related complications in asthma. By targeting mucus characteristics, these findings support future approaches to reduce airway obstruction, enhance lung function, and improve clinical outcomes in patients with severe asthma. A deeper understanding of the glycobiology of mucus is critical to develop new therapies.